Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
NCT02691923Phase 2Active, not recruiting
- Start
- Mar 2016
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorescein sodium 10% injection in glioma (2 arms). Primary endpoint: Fluorescein performance as an intraoperative biomarker for tumor tissue at 24 months. Started Mar 2016; status: active, not recruiting.
02
Drugs
fluorescein sodium 10% injection
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02691923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691923.